Ajanta Pharma Ltd (AJANTPHARM) — shareholding pattern, promoter holding, financials and share price
About Ajanta Pharma Ltd (AJANTPHARM)
Ajanta Pharma Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as AJANTPHARM and on the BSE under scrip code 532331. Its ISIN is INE031B01049.
Ajanta Pharma is primarily engaged in development, manufacturing and marketing of speciality pharmaceutical quality finished dosages.(Source : 202003-01 Annual Report Page No:70).
Ajanta Pharma is a specialty pharmaceutical formulation company focused on Branded Generics across India, Asia and Africa, complemented by a selective US generics business and institutional antimalarial supplies; it develops, manufactures and markets finished dosage formulations from seven manufacturing facilities with an advanced R&D centre and a large front-end salesforce in emerging markets.
The business mix is heavily skewed to Branded Generics (71% of 9M FY2026 sales of Rs. 3,995 crore), with India (31%), Asia (23%) and Africa (17%) the primary markets; Ajanta emphasizes chronic therapies, claims ~50% of products are first-to-market, manages 500+ brands and deploys nearly 6,000 medical representatives globally.
Listed peers in Pharmaceuticals: Ipca Laboratories Ltd, Glaxosmithkline Pharmaceuticals Ltd, Gland Pharma Ltd, J B Chemicals & Pharmaceuticals Ltd, Emcure Pharmaceuticals Ltd, Wockhardt Ltd.
Valuation & Returns
10 Jul 2026At ₹3,359.8 a share on 10 Jul 2026, Ajanta Pharma Ltd (AJANTPHARM) was valued at a price-to-earnings ratio of 39.75x against an industry P/E of 36.41x and a price-to-book of 9.27x on a book value of ₹362.35 per share as of Mar 2026. Solomo computes return on equity of 23.33% and return on capital employed of 29.11% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 39.75x
- Industry P/E
- 36.41x
- P/B
- 9.27x
- EPS (TTM)
- ₹84.52
- Book value / share
- ₹362.35
- ROE
- 23.33%
- ROCE
- 29.11%
- ROA
- 17.16%
- Debt / equity
- 0.06x
- Dividend yield
- 0.83%
- EBITDA margin
- 28.74%
- 52-week range
- ₹2,335 – ₹3,505.55
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Ajanta Pharma Ltd (AJANTPHARM) reported revenue of ₹5,453 crore, net profit of ₹1,056 crore and earnings per share of ₹84.52. That compares with revenue of ₹4,648 crore and net profit of ₹920 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹1,422 crore and net profit ₹267 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 3,341 | 3,743 | 4,209 | 4,648 | 5,453 |
| Net profit (₹ cr) | 713 | 588 | 816 | 920 | 1,056 |
| EPS (₹) | 55.63 | 45.89 | 63.7 | 73.68 | 84.52 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 11.48% | 12.26% | 12.41% | 17.31% |
| Profit growth | 7.36% | 6.98% | 19.22% | 14.73% |
| Stock price CAGR | 13% | 19% | 34% | 24% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 63.48% of Ajanta Pharma Ltd (AJANTPHARM) (down 2.77 pp QoQ), foreign institutional investors (FII) hold 7.68% and domestic institutional investors (DII) hold 21.8%. Promoters have pledged 22.5% of their holding. Market capitalisation was ₹41,976 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: Kotak Flexicap Fund 3.28%, Uti-Flexi Cap Fund 3.11%, Nippon Life India Trustee Ltd-A/C Nippon India Small Cap Fund 2.78%, Aditya Birla Sun Life Trustee Private Limited A/C Aditya Birla Sun Life Midcap Fund 2.21%, Tata Aia Life Insurance Co Ltd-Whole Life Mid Cap Equity Fund-Ulif 009 04/01/07 Wle 110 1.9%, Canara Robeco Mutual Fund A/C Canara Robeco Small Cap Fund 1.46%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 63.48% | 22.5% | 7.68% | 21.8% | 36.52% |
| Mar 2026 | 66.25% | 17.9% | 8.26% | 18.37% | 33.75% |
| Dec 2025 | 66.25% | 17.3% | 7.98% | 18.58% | 33.75% |
| Sep 2025 | 66.25% | 15.3% | 8.53% | 17.9% | 33.75% |
| Jun 2025 | 66.26% | 14.1% | 8.86% | 17.5% | 33.74% |
| Mar 2025 | 66.26% | 12.6% | 8.86% | 17.48% | 33.74% |
| Dec 2024 | 66.26% | 11.2% | 9.26% | 17.02% | 33.74% |
| Sep 2024 | 66.26% | 11.2% | 9.11% | 17.1% | 33.74% |